Sulzberger Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.37M Buy
1,187
+280
+31% +$330K 1.37% 22
2026
Q2
$1.09M Buy
907
+30
+3% +$30.7K 1.06% 25
2026
Q1
$807K Hold
877
– – 0.82% 26
2025
Q4
$943K Buy
877
+26
+3% +$24.9K 0.95% 24
2025
Q3
$649K Buy
851
+9
+1% +$6.7K 0.72% 23
2025
Q2
$656K Sell
842
-72
-8% -$55.9K 0.77% 23
2025
Q1
$755K Sell
914
-718
-44% -$597K 0.99% 20
2024
Q4
$1.26M Buy
+1,632
New +$1.35M 1.42% 19

Other funds holding LLY

Sulzberger Capital Advisors's LLY Position: Q3 2026 in Review

Sulzberger Capital Advisors increased its Eli Lilly (LLY) stake by 31% in Q3 2026, buying an estimated $330K and bringing the position to 1,187 shares worth $1.37M. The position accounts for 1.37% of the portfolio, ranked #22.

Sulzberger Capital Advisors first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Sulzberger Capital Advisors held 1,187 shares of Eli Lilly worth $1.37M as of Q3 2026.
  • Sulzberger Capital Advisors bought 280 Eli Lilly shares in Q3 2026, an estimated $330K.
  • Eli Lilly made up 1.37% of Sulzberger Capital Advisors's portfolio in Q3 2026, its #22 holding.
  • Sulzberger Capital Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Sulzberger Capital Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.